You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Nasopharyngeal carcinoma, antiangiogenesis, HDACi, mTOR, Phase Ib

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Head Neck Cancer, Cervical Cancer, Endometrial Cancer Trial (ILB-2109, Toripalimab)

Not yet recruiting
  • Head and Neck Cancer
  • +9 more
  • (no location specified)
Jul 12, 2023

Nasopharyngeal Carcinoma Trial in Guangzhou (SHR-1701, Gemcitabine, Cisplatin)

Active, not recruiting
  • Nasopharyngeal Carcinoma
  • Guangzhou, Guangdong, China
    Cancer Hospital of Guangzhou Sun Yat-sen University
Dec 19, 2021

NPC Trial in Guangzhou (Sintilimab, IBI310)

Active, not recruiting
  • NPC
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 3, 2022

Head and Neck Squamous Cell Carcinoma Trial (Sapropterin diHCl tablets)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Sapropterin dihydrochloride tablets
  • (no location specified)
Mar 17, 2022

Carcinoma, Squamous Cell of Head and Neck, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Hypopharyngeal Cancer Trial in

Completed
  • Carcinoma, Squamous Cell of Head and Neck
  • +5 more
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Jan 24, 2022

Immunotherapy With Pembrolizumab for Nasopharyngeal Carcinoma Patients Trial in Taiwan (Pembrolizumab)

Terminated
  • Immunotherapy With Pembrolizumab for Nasopharyngeal Carcinoma Patients
  • Changhua, Taiwan
  • +7 more
Apr 5, 2022

Nasopharyngeal Carcinoma Trial in Guangzhou (Bevacizumab+Toripalimab+gemcitabine, adjuvant with Bevacizumab and Toripalimab,

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • Bevacizumab+Toripalimab+gemcitabine, adjuvant with Bevacizumab and Toripalimab
  • Bevacizumab+Toripalimab+gemcitabine, adjuvant with Toripalimab
  • Guangzhou, Guangdong, China
    Department of Nasopharyngeal Carcinoma, Sun Yat-sen University C
Apr 18, 2022

Solid Tumor, Immune Checkpoint Inhibitor, Intestinal Flora Trial in Guangzhou (RX-af01)

Recruiting
  • Solid Tumor
  • +2 more
  • Guangzhou, Guangdong, China
    Miao-Zhen Qiu
Oct 8, 2022

Advanced Solid Tumor Trial in China (LBL-007 Injection, Toripalimab Injection)

Recruiting
  • Advanced Solid Tumor
  • LBL-007 Injection
  • Toripalimab Injection
  • Bengbu, Anhui, China
  • +12 more
Nov 18, 2022

Glioblastoma, Recurrent Glioblastoma Trial in San Francisco (RMC-5552)

Not yet recruiting
  • Glioblastoma
  • Recurrent Glioblastoma
  • San Francisco, California
    University of California, San Francisco
Nov 28, 2022

Nasopharyngeal Carcinoma Screening Based on Tongue Imaging

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • Tongue image
  • Zhuhai, China
    The Fifth Affiliated Hospital of Sun Yat sen University
Nov 10, 2023

Nasopharyngeal Carcinoma Trial in Zhongshan (Anrotinib plus Tirelizumab)

Recruiting
  • Nasopharyngeal Carcinoma
  • Anrotinib plus Tirelizumab
  • Zhongshan, Guangdong, China
    Zhongshan City People's Hospital
Jul 31, 2023

Nasopharyngeal Carcinoma Trial in Wuhan (Cadonilimab)

Recruiting
  • Nasopharyngeal Carcinoma
  • Wuhan, Hubei, China
    Union Hospital, Tongji Medical College, Huazhong University of S
Mar 27, 2023

Nasopharyngeal Carcinoma Trial in Wuhan (KSD-101)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • KSD-101
  • Wuhan, China
    Tongji Hospital, Tongji Medical College, Huazhong University of
Oct 19, 2023

Nasopharyngeal Carcinoma Trial (Envafolimab and recombinant human endostatin combined with chemoradiotherapy)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • Envafolimab and recombinant human endostatin combined with chemoradiotherapy
  • (no location specified)
Sep 23, 2023

Hepatocellular Carcinoma Trial in Shanghai (BC3402 injection, Durvalumab injection)

Not yet recruiting
  • Hepatocellular Carcinoma
  • BC3402 injection
  • Durvalumab injection
  • Shanghai, China
    Zhongshan Hospital, Fudan University
Oct 26, 2023

Nasopharyngeal Carcinoma Trial in Guangzhou, Zhongshan, Nanning (IMRT and concurrent cisplatin, gemcitabine and cisplatin

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • IMRT and concurrent cisplatin
  • gemcitabine and cisplatin (Induction chemotherapy)
  • Guangzhou, Guangdong, China
  • +3 more
Jul 30, 2023

Nasopharyngeal Carcinoma, Recurrent Cancer Trial in Guangzhou (Tranilast)

Recruiting
  • Nasopharyngeal Carcinoma
  • Recurrent Cancer
  • Guangzhou, Guangdong, China
    Southern medical university
Nov 15, 2022

NSCLC, Nasopharyngeal Carcinoma Trial in China (BL-B01D1, SI-B003)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Nasopharyngeal Carcinoma
  • Chongqing, Chongqing, China
  • +15 more
Jul 13, 2023

Advanced Nasopharyngeal Carcinoma Trial in Guangzhou (Toripalimab injection(subcutaneous)/JS001sc, Toripalimab /JS001)

Recruiting
  • Advanced Nasopharyngeal Carcinoma
  • Toripalimab injection(subcutaneous)/JS001sc
  • Toripalimab /JS001
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Feb 21, 2023

Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Endometrial Adenocarcinoma Trial in Houston (Copanlisib,

Recruiting
  • Deleterious BRCA1 Gene Mutation
  • +10 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 23, 2022

Advanced Hepatocellular Carcinoma Trial in Guangzhou (adebrelimab, camrelizumab plus apatinib)

Not yet recruiting
  • Advanced Hepatocellular Carcinoma
  • adebrelimab, camrelizumab plus apatinib
  • Guangzhou, Guangdong, China
    Sun Yat-sen Memorial Hospital
Jun 21, 2023

Nasopharyngeal Carcinoma Trial in Hangzhou (Endostar and Envafolimab)

Recruiting
  • Nasopharyngeal Carcinoma
  • Endostar and Envafolimab
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Sep 24, 2023

Advanced Nasopharyngeal Carcinoma Trial in Hangzhou (SBRT)

Recruiting
  • Advanced Nasopharyngeal Carcinoma
  • SBRT
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Dec 5, 2022

Nasopharyngeal Carcinoma Trial in Guangzhou (BL-B01D1, capecitabine, gemcitabine)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 31, 2023